C07K 2317/41
Glycosylation, sialylation, or fucosylation
C07K2317/41 (Glycosylation, sialylation, or fucosylation) appears on 1,505 US grants and 3,061 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,505
- Published applications
- 3,061
- Assignees
- 837
- Inventors
- 4,782
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 4 | 0 |
| 1997 | 0 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 5 | 0 |
| 2002 | 1 | 10 |
| 2003 | 2 | 13 |
| 2004 | 5 | 28 |
| 2005 | 4 | 31 |
| 2006 | 1 | 46 |
| 2007 | 1 | 57 |
| 2008 | 9 | 47 |
| 2009 | 16 | 68 |
| 2010 | 35 | 83 |
| 2011 | 35 | 89 |
| 2012 | 47 | 105 |
| 2013 | 66 | 96 |
| 2014 | 68 | 154 |
| 2015 | 85 | 169 |
| 2016 | 89 | 191 |
| 2017 | 121 | 192 |
| 2018 | 90 | 163 |
| 2019 | 126 | 199 |
| 2020 | 113 | 214 |
| 2021 | 106 | 184 |
| 2022 | 84 | 197 |
| 2023 | 107 | 177 |
| 2024 | 104 | 216 |
| 2025 | 116 | 207 |
| 2026 | 60 | 125 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Anti-CCR8 antibodies for treating cancer29 Sep 2026US 12,747,296 B2Bristol-Myers Squibb Company
- Epithelial cadherin-specific antibodies15 Sep 2026US 12,735,498 B2Kling Biotherapeutics B.V.
- Antibodies that bind to human chemokine (C-C motif) receptor 8 (CCR8)8 Sep 2026US 12,729,241 B2Gilead Sciences, Inc.
- Humanized antibodies directed against KCNK91 Sep 2026US 12,723,075 B2Kennedy Krieger Institute, Inc.
- Methods of treating colorectal cancer using a combination of a ctla-4 inhibitor and a pd-1 inhibitor8 Oct 2026US 2026/0308257 A1Agenus Inc.
- Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases8 Oct 2026US 2026/0308261 A1Konkuk University Industrial Cooperation Corp.
- Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof8 Oct 2026US 2026/0308274 A1Genentech, Inc.
- Risankizumab compositions1 Oct 2026US 2026/0297178 A1AbbVie Inc.
- Novel EGFR Binding Proteins1 Oct 2026US 2026/0297200 A1
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity604US 6,602,684 B1GlycArt Biotechnology AG · 2003
- Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells304US 5,789,554 AImmunomedics, Inc. · 1998
- Cells producing antibody compositions with increased antibody dependent cytotoxic activity247US 6,946,292 B2Kyowa Hakko Kogyo Co., Ltd. · 2005
- Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells237US 6,187,287 B1Immunomedics, Inc. · 2001